Αποτελέσματα Αναζήτησης
12 Σεπ 2023 · Section 2 examines how ADNI data have directly contributed to the development of AD therapies, describes important data harmonization efforts, outlines progress in the development of plasma biomarkers for clinical use, and reviews diagnostic and prognostic models.
Results. CSFAD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non-ADNI living subjects followed by the autopsy confirmation of AD.
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD).
1 Ιουν 2015 · Abstract. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD).
This paper reviews the current status of the Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project.
1 Μαΐ 2010 · The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD).
4 Αυγ 2014 · The aim of the current study was to investigate the compatibility of the 3.0T ADNI-1 and ADNI-2 T1-weighted volumes using VBM. The main parameters that differed between the ADNI-1 and ADNI-2 pulse sequences were TR time and flip angle.
